The current PE ratio for Astrazeneca stock as of May 12, 2025 is 27.47. This is calculated based on the TTM EPS of $2.51 and the stock price of $68.95 per share. The PE ratio marks a decrease of 17% from its last 4 quarters average of 33.2.
The average historical PE ratio of Astrazeneca for the last ten years is 81.35. The current P/E ratio of 27.47 is 66% lower than the historical average. Looking back at the last ten years, AZN's PE ratio peaked in the Dec 2021 quarter at 1,456.25, when the price was $58.25 and the EPS was $0.04. The lowest point was in the Dec 2016 quarter, when it reached 19.65 with a price of $27.32 and an EPS of $1.39.
Maximum annual increase: 3,453.56% in 2021
Maximum annual decrease: -95.61% in 2022
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
2024 | 28.86 | -17.73% | $65.52 | $2.27 |
2023 | 35.08 | -45.15% | $67.35 | $1.92 |
2022 | 63.96 | -95.61% | $67.8 | $1.06 |
2021 | 1,456.25 | 3,453.56% | $58.25 | $0.04 |
2020 | 40.98 | -57.26% | $49.99 | $1.22 |
2019 | 95.88 | 114.59% | $49.86 | $0.52 |
2018 | 44.68 | 53.22% | $37.98 | $0.85 |
2017 | 29.16 | 48.4% | $34.7 | $1.19 |
2016 | 19.65 | -35.17% | $27.32 | $1.39 |
2015 | 30.31 | -57.8% | $33.95 | $1.12 |
2014 | 71.82 | 146.8% | $35.19 | $0.49 |
2013 | 29.1 | 205.35% | $29.69 | $1.02 |
2012 | 9.53 | 50.32% | $23.64 | $2.48 |
2011 | 6.34 | -23.15% | $23.15 | $3.65 |
2010 | 8.25 | -8.64% | $23.1 | $2.8 |
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
Mar 2025 | 29.28 | 1.46% | $73.5 | $2.51 |
Dec 2024 | 28.86 | -22.21% | $65.52 | $2.27 |
Sep 2024 | 37.1 | -1.07% | $77.91 | $2.1 |
Jun 2024 | 37.5 | 13.46% | $77.99 | $2.08 |
Mar 2024 | 33.05 | -5.79% | $67.75 | $2.05 |
Dec 2023 | 35.08 | -1.57% | $67.35 | $1.92 |
Sep 2023 | 35.64 | -0.89% | $67.72 | $1.9 |
Jun 2023 | 35.96 | -21.24% | $71.57 | $1.99 |
Mar 2023 | 45.66 | -28.61% | $69.41 | $1.52 |
Dec 2022 | 63.96 | -34.69% | $67.8 | $1.06 |
Sep 2022 | 97.93 | N/A | $54.84 | $0.56 |
Jun 2022 | N/A | N/A | $66.07 | -$0.53 |
Mar 2022 | N/A | N/A | $66.34 | -$0.43 |
Dec 2021 | 1,456.25 | 1,476.03% | $58.25 | $0.04 |
Sep 2021 | 92.4 | 122.12% | $60.06 | $0.65 |
Currently, AZN's PE ratio is lower than its 3, 5 and 10-year averages.
In comparison to its peer LLY, AZN's PE ratio is lower, but it is higher than JNJ's and ABT's. Astrazeneca's PE ratio is trading above the peer average of 21.35.
Stock name | PE ratio | Market cap |
---|---|---|
MRK Merck & Co Inc | 11.67 | $201.96B |
BIIB Biogen Inc | 12.24 | $18.23B |
PFE Pfizer Inc | 16.61 | $131.28B |
NVS Novartis AG | 16.92 | $213.47B |
JNJ Johnson & Johnson | 17.01 | $370.87B |
ABT Abbott Laboratories | 17.1 | $229.64B |
BMY Bristol Myers Squibb Co | 17.98 | $98.05B |
AZN Astrazeneca plc | 27.47 | $213.75B |
LLY ELI LILLY & Co | 61.23 | $716.08B |
AZN stock has a price to earnings ratio of 27.47 as of May 12, 2025.
The 3-year average price to earnings ratio for AZN stock is 43.64.
The 5-year average price to earnings ratio for AZN stock is 125.9.
Over the last ten years, the quarterly PE ratio reached its highest level at 1,456.25 in the Dec 2021 quarter.
The current PE ratio of AZN is 66% lower than the 10-year historical average.
You can calculate the P/E ratio by dividing the most recent stock price by the trailing twelve months EPS. As of today (May 12, 2025), Astrazeneca's share price is $68.95. The company's earnings per share for the trailing twelve months (TTM) ending Mar 2025 is $2.51. Therefore, Astrazeneca's PE ratio for today is 27.47. PE RATIO(27.47) = STOCK PRICE($68.95) / TTM EPS($2.51)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.